Ann: New Pre-Clinical Collaboration on PAT-DX1, page-2

1
ASX & Media Release
Pilot Study Leads to New Pre-Clinical
Collaboration on PAT-DX1
Melbourne, Australia; 17 May, 2018: Patrys Limited (ASX: PAB), a therapeutic antibody
development company, is pleased to announce that following the completion of a pilot study, it has
initiated a research and development collaboration that brings together experts from Yale School of
Medicine in New Haven, Connecticut and Beth Israel Deaconess Medical Center (BIDMC) in Boston,
Massachusetts.
The pilot study showed that PAT‐DX1 has antitumor activity in an orthotopic, immune‐competent
mouse model of triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer.
The expanded research program will be led by Dr. James Hansen of Yale and Drs. Gerburg Wulf and
Jaymin Patel of BIDMC, and will further investigate PAT‐DX1 in BIDMC’s orthotopic, immune‐
competent mouse model of TNBC.
Dr. Hansen is an expert in cell‐penetrating antibodies and is inventor of the Deoxymab technology.
Dr. Wulf has significant experience in the development and testing of new drug combinations that
may improve outcomes in TNBC. Dr. Patel’s translational research in the field of breast cancer spans
nanoparticle technology, genomic instability, DNA damage repair (DDR), tumor targeting and
personalized medicine.
“Patrys is delighted to continue our work with Dr. Hansen and to establish new collaborations with
Dr. Patel and Dr. Wulf, all of them outstanding clinician‐researchers whose expertise spans from the
laboratory to the clinic. The opportunity to build on the successful pilot study and to further
investigate PAT‐DX1 in an immunocompetent mouse model of TNBC is timely, following the
successful completion of the PAT‐DX1 orthotopic glioblastoma study completed at Yale University in
March,” said Dr. James Campbell, Chief Executive Officer and Managing Director of Patrys.
“Patrys’ novel position in the field of DNA damage repair antibody therapeutics is increasingly being
recognized, resulting in collaborations such as this one between the company, Yale University and
the Beth Israel Deaconess Medical Center”, added Dr. Campbell
Patrys will make a statement on the research findings upon completion and publication of the study.


That was nice timing